| [1] |
中国临床肿瘤学会胃肠间质瘤专家委员会，中国抗癌协会胃肠间质瘤专业委员会，中国医师协会外科医师分会胃肠道间质瘤诊疗专业委员会. 胃肠间质瘤基因检测与临床应用的中国专家共识（2021版）［J］. 临床肿瘤学杂志，2021，26（10）：920-927.
|
| [2] |
Zhu CZ，Liu D，Kang WM，et al. Ghrelin and gastrointestinal stromal tumors［J］. World J Gastroenterol，2017，23（10）：1758-1763.
|
| [3] |
Serrano C，Marino-Enriquez A，Tao DL，et al. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours［J］. Br J Cancer，2019，120（6）：612-620.
|
| [4] |
王峰，宋鹏，汪灏，等. 284例胃间质瘤临床特征及预后分析［J/CD］. 中华普外科手术学杂志（电子版），2017，11（02）：123-126.
|
| [5] |
Boichuk S，Galembikova A，Mikheeva E，et al. Inhibition of FGF2-Mediated Signaling in GIST-Promising Approach for Overcoming Resistance to Imatinib［J］. Cancers（Basel），2020，12（6）：1674.
|
| [6] |
Heinrich MC，Jones RL，Mehren MV，et al. Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor（GIST）［J］. J Clin Oncol，35，2017：11011-11011.
|
| [7] |
张玉，缪丽燕. 胃肠间质瘤靶向药物的治疗药物监测中国专家共识［J］. 中国医院药学杂志，2021，41（20）：2041-2049.
|
| [8] |
Lin JX，Chen QF，Zheng CH，et al. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor？A study based on long-term follow-up［J］. J Cancer Res Clin Oncol，2017，143（4）：727-734.
|
| [9] |
于恒，杜尚策，徐恩，等. 影响胃肠道间质瘤预后因素的研究进展［J/CD］. 中华普外科手术学杂志（电子版），2020，14（01）：97-100.
|
| [10] |
王峰，于恒，王萌，等. 中高危险度胃肠间质瘤患者术后治疗的预后分析［J/CD］. 中华普外科手术学杂志（电子版），2021，15（04）：460-463.
|
| [11] |
张宁，刘蓉，丁乾坤. 舒尼替尼治疗伊马替尼耐药胃肠间质瘤的疗效观察［J］. 中国肿瘤临床与康复，2021，28（05）：590-594.
|
| [12] |
魏星. 免疫治疗［J］. 中国科技术语，2019，21（02）：79-80.
|
| [13] |
Sun J，Zheng Y，Mamun M，et al. Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors［J］. Biomedi Pharmacother，2020，129：110504.
|
| [14] |
Vallilas C，Sarantis P，Kyriazoglou A，et al. Gastrointestinal Stromal Tumors（GISTs）：Novel Therapeutic Strategies with Immunotherapy and Small Molecules［J］. Int J Mol Sci，2021，22（2）：493.
|
| [15] |
Pantaleo MA，Tarantino G，Agostinelli C，et al. Immune microenvironment profiling of gastrointestinal stromal tumors（GIST）shows gene expression patterns associated to immune checkpoint inhibitors response［J］. Oncoimmunology，2019，8（9）：e1617588.
|
| [16] |
Blakely AM，Matoso A，Patil PA，et al. Role of immune microenvironment in gastrointestinal stromal tumours［J］. Histopathology，2018，72（3）：405-413.
|
| [17] |
Labadie BW，Bao R，Luke JJ. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis［J］. Clin Cancer Res，2019，25（5）：1462-1471.
|
| [18] |
D'Angelo SP，Shoushtari AN，Keohan ML，et al. Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas：A Phase Ib Study of Dasatinib plus Ipilimumab［J］. Clin Cancer Res，2017，23（12）：2972-2980.
|
| [19] |
Dugage MR，Jones RL，Trent J，et al. Beyond the Driver Mutation：Immunotherapies in Gastrointestinal Stromal Tumors［J］. Front Immunol，2021，12：715727.
|
| [20] |
Marcq E，Siozopoulou V，De Waele J，et al. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma［J］. Oncoimmunology，2017，6（1）：e1261241.
|
| [21] |
Zhao R，Song Y，Wang Y，et al. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway［J］. Cell Prolif，2019，52（3）：e12571.
|
| [22] |
Zhang JQ，Zeng S，Vitiello GA，et al. Macrophages and CD8（+）T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors［J］. Cancer immunol Res，2018，6（4）：434-447.
|
| [23] |
Tan Y，Trent JC，Wilky BA，et al. Current status of immunotherapy for gastrointestinal stromal tumor［J］. Cancer Gene Ther，2017，24（3）：130-133.
|
| [24] |
Zhang Y，Zhang Z. The history and advances in cancer immunotherapy：understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications［J］. Cell Mol Immunol，2020，17（8）：807-821.
|
| [25] |
Abrams T，Connor A，Fanton C，et al. Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors［J］. Clin Cancer Res，2018，24（17）：4297-4308.
|
| [26] |
Abrams T，Connor A，Fanton C，et al. Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody Drug Conjugate against Mutant and Wild Type c-KIT Positive Solid Tumors［J］. Clinical Cancer Res，2018，24（17）：4297-4308.
|
| [27] |
Loaiza-Bonilla A，Bonilla-Reyes PA. Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors：Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy［J］. Cureus，2017，9（9）：e1710.
|
| [28] |
Yuki K，Cheng N，Nakano M，et al. Organoid Models of Tumor Immunology［J］. Trends Immunol，2020，41（8）：652-664.
|
| [29] |
Bader JE，Voss K，Rathmell JC. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy［J］. Mol Cell，2020，78（6）：1019-1033.
|
| [30] |
Leko V，Rosenberg SA. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors［J］. Cancer Cell，2020，38（4）：454-472.
|
| [31] |
Andrejeva G，Rathmell JC. Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors［J］. Cell Metab，2017，26（1）：49-70.
|
| [32] |
Garcia-Valverde A，Rosell J，Sayols S，et al. E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor［J］. Oncogene，2021，40（48）：6614-6626.
|
| [33] |
Catalán M，Olmedo I，Faúndez J，et al. Medicinal Chemistry Targeting Mitochondria：From New Vehicles and Pharmacophore Groups to Old Drugs with Mitochondrial Activity［J］. Int J Mol Sci，2020，21（22）：8464.
|
| [34] |
Vitiello GA，Medina BD，Zeng S，et al. Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor［J］. Clin Cancer Res，2018，24（4）：972-984.
|